ELQ-300 Prodrugs for Enhanced Delivery and Single-Dose Cure of Malaria

ELQ-300 is a preclinical candidate that targets the liver and blood stages of Plasmodium falciparum, as well as the forms that are crucial to transmission of disease: gametocytes, zygotes, and ookinetes. A significant obstacle to the clinical development of ELQ-300 is related to its physicochemical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrob Agents Chemother
Hauptverfasser: Miley, Galen P., Pou, Sovitj, Winter, Rolf, Nilsen, Aaron, Li, Yuexin, Kelly, Jane X., Stickles, Allison M., Mather, Michael W., Forquer, Isaac P., Pershing, April M., White, Karen, Shackleford, David, Saunders, Jessica, Chen, Gong, Ting, Li-Min, Kim, Kami, Zakharov, Lev N., Donini, Cristina, Burrows, Jeremy N., Vaidya, Akhil B., Charman, Susan A., Riscoe, Michael K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2015
Schlagworte:
Experimental Therapeutics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4538462/
https://ncbi.nlm.nih.gov/pubmed/26124159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01183-15
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge